https://doi.org/10.4081/hmr.v1i8.291

Beyond bortezomib alone: combination therapy and new strategies in targeting the proteasome

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 139
PDF: 225
Untitled (): 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

PG Richardson
support@pagepress.org
Bortezomib is a selective proteasome inhibitor that has exhibited anti-proliferative, pro-apoptotic, and anti-angiogenic properties in myeloma models.1-4 These effects result from activation or inactivation of multiple signaling pathways. In multiple myeloma (MM) cell lines, bortezomib induced downregulation of growth and survival signals as well as upregulation of apoptotic pathways, including mitochondrial release of cytochrome c and activation of JNK, caspase-3 and -8.3 Bortezomib also inhibited activation of nuclear factor-kappaB, through stabilization of inhibitor-kappaB, resulting in decreased interleukin-6 secretion, apoptosis, and chemosensitization of MM cells.1-4 Importantly, MM cells were 170 times more sensitive than normal cells to bortezomib-induced apoptosis.1

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Richardson, P. (2009). Beyond bortezomib alone: combination therapy and new strategies in targeting the proteasome. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.291
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).